NCT02281292View on ClinicalTrials.gov

A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

LKA651 ophthalmic solution

BIOLOGICAL

Ranibizumab ophthalmic solution

BIOLOGICAL

Sham injection

Mock injection administered as an empty hub without needle

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
collaborator

Novartis Institutes for BioMedical Research

OTHER

lead

Alcon Research

INDUSTRY